As a result, cancer cells continue to proliferate despite BCR-ABL suppression and clinically, this means that some CML patients may be resistant to all available TKIs [18,19]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.